---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-086933"
form_type: "8-K"
ticker: "ORKA"
cik: "0000907654"
company_name: "Oruka Therapeutics, Inc."
filed_at: "2026-08-10T11:00:41+00:00"
generated_at: "2026-08-10T11:05:59.784790+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Oruka Q2 net loss $41.2M; EVERLAST-A 63.5% PASI 100; cash $1.1B

## Summary
- Q2 2026 net loss $41.2M vs $24.6M in Q2 2025; R&D spend $43.3M; cash $1.1B funds through BLA filing.
- EVERLAST-A Phase 2a: 40/63 (63.5%) achieved PASI 100 at Week 16; PASI 90 83%; IGA 0/1 84%.
- EVERLAST-B fully enrolled (187 subjects); Week 16 data expected Q4 2026; Phase 3 for ORKA-001 in 1H 2027.
- ORCA-SPLASH Phase 2 in HS initiated (~160 patients); ORKA-004 TL1A antibody enters clinic Q4 2026.
- May 2026: IL-23 license with Paragon amended to include all therapeutic areas incl. IBD.

## SEC filing metadata
- accession: 0001213900-26-086933
- form_type: 8-K
- ticker: ORKA
- cik: 0000907654
- company_name: Oruka Therapeutics, Inc.
- filed_at: 2026-08-10T11:00:41+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/907654/000121390026086933/0001213900-26-086933-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/907654/000121390026086933/ea0301312-8k_oruka.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-086933
- JSON: https://secwatch.observer/filing/0001213900-26-086933.json
- Plain text: https://secwatch.observer/filing/0001213900-26-086933.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.